ClinicalTrials.gg
CompletedNCT07115498iTAGUpdated May 12, 2026

Piloting the Incentivized Text-Based Adherence Game Intervention.

An interventional study of iTAG in HIV Treatment Adherence, sponsored by Providence College. Completed at 1 site in Ghana. Open to participants aged 18 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Providence College · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 24 Years
Sex
All
01

Study summary

This project will develop and test a novel intervention to improve HIV treatment adherence among young adults with HIV who attend an HIV clinic in Kumasi, Ghana. The intervention is called incentivized Text-Based Adherence Game (iTAG). It is delivered solely via text messages and includes many advanced features including a point system that rewards participants for responding to texts, a scoreboard that compares participants' progress with each other, and messages on a range of health and HIV-related topics. To evaluate iTAG, study staff will recruit 20 young people, ages 18-24, with HIV (YPWH) to complete 90 days worth of intervention text messages. Before and after receiving iTAG messages, they will complete computer assessments used to measure HIV medication adherence as well as other factors believed to be influence adherence such as social support. By examining participants score from before and after receiving the intervention, and by talking with participants after they receive the intervention, it will be understood whether iTAG is acceptable to YPWH and could potential lead to improvements in participants' HIV treatment adherence.

Read the detailed description

The current study has three aims revolved around developing and testing an intervention, called the incentivized Text-Based Adherence Game (iTAG) which is a text message-delivered intervention to improve HIV treatment adherence among Ghanaian young people with HIV (YPWH(). It expands on a prior intervention, called TAG, which used gamification strategies to improve adherence among YPWH by incorporate economic empowerment strategies including small conditional economic incentives and a peer-led mutual savings account. The central premise guiding this work is that iTAG is a feasible, acceptable, and potentially effective way to further engage YPWH in HIV care. As one of the study aims, iTAG will be evaluated with a single-arm pilot trial by examining YPH (N = 20-25) over 12 weeks on outcome trends, i.e., treatment adherence (i.e., antiretroviral use, viral load) and potential mediators (e.g., financial insecurity), acceptability, and indicators of feasibility and implementation potential (e.g., SMS response rate).

The single-arm pilot trial (N = 25 YPWH) will have a 12-week intervention period with pre- and-post-intervention assessments. Survey assessments will occur using an audio-assisted computer self-interview (ACASI) completed in a private space at an HIV clinic in Ghana. A post-intervention interview will also be conducted with 8 participants. Participants will be compensated for each assessment and receive phone credits for iTAG.

Final content, format, and delivery of iTAG will be determined after a prior Development Phase. Initial content, format, and delivery will be based on TAG and are as follows. YPWH receive four types of automated and tailored SMS: adherence messages (i.e., medication and clinic appointment reminders), skill messages on topics related to adherence, and story messages (i.e., SMS related to the game's storyline). Gamification strategies include themed messages, a point/reward system, and a weekly scoreboard message. Messages will also offer linkage to social support and clinic services by triggering email alerts to research staff. In addition, participants will be given opportunities to cash-in game points for mobile money or donate incentives to a mutual savings account. Code words will be used for all HIV-related topics and participants will use pseudonyms to protect privacy.

Survey assessments will be administered by SurveyToGo, an ACASI system, on tablets. The cloud system allows for encrypted storing and transfer of de-identified data collected in Ghana to research staff in the US. Participants will complete the Session Evaluation Form and the Client Satisfaction Questionnaire to assess intervention acceptability. Analytic data will also show text message (SMS) interactions for the purpose of assessing feasibility and engagement. Main outcomes will include (1) self-report of past 30-day ART adherence using a 3-item measure and (2) viral load (log10). Staff will abstract medical chart data and if viral load was not measured in the past 3 months (pre-intervention) or 1 month (post-intervention), it will be assessed at this visit as part of routine care. Secondary outcomes will also be assessed including relevant knowledge (e.g., HIV knowledge), beliefs/attitudes (e.g., attitudes towards ART), and behavior (e.g., treatment self-efficacy), social support, access to services/resources and economic wellbeing (e.g., food insecurity). A 15-min interview will also be conducted with 8 participants to further examine iTAG's acceptability and implementation potential.

Intervention acceptability will be determined using the criteria of mean scores ≥ 24 on the CSQ and ≥30 on the SEF defined as acceptable. An SMS/voice message response/receipt rate of 80% will be deemed as acceptable. To examine outcome trends, the investigators have the following hypothesis: among the YPWH enrolled, at post-intervention, YPWH will demonstrate trends towards an increase in ART adherence and decrease in viral load (log10). They will also show improvements in secondary outcomes. Pre-post intervention differences in these outcomes will be explored using a repeated measures t-test and the Cohen's d effect size

02

Conditions studied

  • HIV Treatment Adherence
03

In context

Treatment Adherence and Compliance

353 studies on the registry are indexed under Treatment Adherence and Compliance; 108 are open to participants now.

This study's enrollment of 21 is below the median of 83 across 273 interventional studies indexed under Treatment Adherence and Compliance.

Browse Treatment Adherence and Compliance studies →

Lead sponsor

Providence College is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between ages 18-24
  • In treatment for at our recruitment site
  • Read English and speak English or a language spoken by clinic staff
  • On ART medication
  • Own a mobile phone
  • Evidence of recent ART non-adherence
  • Evidence of a detectable viral load in the past 3 months

Exclusion criteria

Exclusion Criteria:

  • Physically or cognitively impaired
  • Participation in another ART adherence intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    iTAG

    Participants in this arm receive the iTAG intervention.

    Behavioral: iTAG

Interventions

  • BehavioraliTAG

    Participants in this intervention start by receiving a brief (15 minute) in-person standard-of-care counseling session focused on increasing their knowledge of HIV treatment adherence and strategies to improve adherence. Following this session, they will then receive daily or less frequent text messages (SMS) over the course of three months. Messages are primary two-way, automated, and have preprogrammed response options. Message content includes HIV medication reminders, motivational messages, information on topics relevant to HIV treatment (e.g., HIV disclosure) in the form of quizzes, opportunities to reach out for support from clinic staff or peer mentors, and game-based messages including story messages, a weekly scoreboard, point system progress, and peer interactions.

06

What researchers measure

Primary outcomes

  1. 3-item measure of antiretroviral therapy (ART) adherence

    This 3-item self-report survey measure assesses recent ART adherence (Wilson et al., 2016). Wilson, I. B., Lee, Y., Michaud, J., Fowler Jr, F. J., \& Rogers, W. H. (2016). Validation of a new three-item self-report measure for medication adherence. AIDS and Behavior, 20(11), 2700-2708.

    Time frame: 30 days

  2. HIV viral load

    This measure is the biological assessment HIV viral load via blood draw. Consistent with prior studies, viral load will be statistically transformed (log10) to correct for skewness.

    Time frame: Viral load testing must have been performed in past 3 months for the baseline assessment and in the past month for the 3-month follow-up assessment.

07

Study locations

1 site
  • Komfo Anokye Teaching Hospital
    Kumasi, Ghana
08

References and documents

Individual participant data

Plan to share: Yes — IPD on select demographic variables (e.g., gender), main outcomes (e.g., viral load), and secondary outcomes (e.g., financial behavior) will be shared.

Time frame: IPD will be accessible beginning 5/7/2026 and ending 5/7/2029.

Access criteria: IDP associated with this small trial, including participants' de-identified demographic information, main outcomes, and secondary outcomes, may be obtained by contacting the study's PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Nov 2025, 5 months.

Of 180 non-industry interventional studies with no phase under Treatment Adherence and Compliance, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 5 months is below that.

Counting every sponsor, half of 185 studies reached it within 17 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
May 16, 2025
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 13, 2025
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07115498
Lead sponsor
Providence College
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
May 16, 2025
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion